Mitsui & Co., Ltd.

Cancer research can move faster when clinical data is used responsibly, without compromising privacy. We’re pleased to share that Mitsui has entered a service agreement with Oncoshot to leverage its proprietary clinical data analytics technology. As the largest shareholder of IHH Healthcare, Mitsui aims to support international collaborative research by connecting oncology specialists across the Asia-Pacific region and fostering knowledge exchange with leading global institutions such as Memorial Sloan Kettering Cancer Center (MSK). Across clinical research, drug discovery, and trial design, demand for high-quality clinical data continues to rise. Yet much of that data remains fragmented and unstructured within individual institutions. Privacy regulations and institution-specific data governance can also limit how data is transferred and used. These constraints have made access to high-quality clinical data, particularly from diverse Asian patient populations, more difficult than it should be. Oncoshot’s AI-powered technology anonymizes and structures data within healthcare institutions, including electronic medical records and lab results, transforming it into datasets that can support research and drug development without requiring the underlying data to leave the institution. This approach can help accelerate data utilization while respecting strict privacy, access, and governance requirements. Through this collaboration, we aim to advance our “Wellness Ecosystem Creation 2.0” initiative by helping to shorten clinical study timelines, strengthen evidence from diverse populations, and create more opportunities for international knowledge exchange. Ultimately, we hope these efforts will help expand access to innovative treatment options and improve the quality of cancer care across the Asia-Pacific region. Read more: https://lnkd.in/g6BzP5sm #MitsuiandCo #HealthcareInnovation #DigitalHealth #RealWorldData #Oncology #CancerResearch #HealthTech #ClinicalResearch

We are pleased to share two developments that will strengthen Mitsui & Co.’s Food Science business: bringing the production of key upstream materials for Nutrinova in-house, and increasing Mitsui’s stake in Nutrinova Netherlands B.V., our equity-method affiliate in functional food ingredients. Mitsui first invested in Nutrinova in the fiscal year ended March 2024 and has since operated the business alongside Celanese Corporation, producing and marketing ingredients found in food and beverages worldwide, including the high-intensity sweetener acesulfame potassium (Ace-K) and the preservatives sorbic acid and potassium sorbate. These products rely on essential intermediates supplied by VP4 Frankfurt GmbH in Germany. By integrating this upstream production into Nutrinova, we will connect more of the value chain from raw materials through to finished products, helping to enhance supply reliability and cost competitiveness while bringing quality and supply chain management under a unified structure. At the same time, Mitsui will acquire a further 19% of Nutrinova from Celanese, increasing its holding to 89%. Nutrinova will subsequently become a consolidated subsidiary of Mitsui, enabling Mitsui to act more decisively and execute Nutrinova’s strategy more effectively. These investments will support the expansion of our Food Science business under “Wellness Ecosystem Creation 2.0,” one of the strategic priorities of Mitsui’s Medium-term Management Plan 2029. Building on Nutrinova’s portfolio of high-intensity sweeteners, preservatives, and other functional ingredients, we aim to strengthen the business while moving beyond ingredient supply by connecting more closely with the capabilities needed to deliver tailored solutions for customers. Through these efforts, we remain committed to contributing to a stable food supply and helping people everywhere live healthier, richer lives. Learn more: https://lnkd.in/dxxABUUA #MitsuiandCo #FoodScience #FoodSupply #FoodIndustry #FunctionalIngredients #Wellness

We are pleased to announce that our Human Capital Report 2026 is now available. We have consistently believed that “people” are the source of our sustainable value creation and have dedicated ourselves to acquiring and developing talent, continuous talent development, and organizational development. This report introduces our value creation process, focusing on “people” within our global group, and organizes and summarizes our various initiatives for human capital. In this year's edition, we have incorporated our newly announced Medium-term Management Plan 2029, updated our CHRO interview, and further enhanced the disclosure of human capital initiatives and performance indicators. Read the Human Capital Report 2026 here: https://lnkd.in/ga_xmCwi

Watch this series as Mitsui & Co. introduces "Wellness Ecosystem Creation," one of its strategic initiatives, which aims to build an environment where people around the world can live healthy lives by providing optimal food and healthcare tailored to individual needs. Watch the full series: https://lnkd.in/gaTzSWNk

Watch this series as Mitsui & Co. highlights "Global Energy Transition," one of its key strategic initiatives, focusing on investments in rooftop solar power generation, EV smart charging, energy storage solutions, and next-generation fuels. Watch the full series: https://lnkd.in/guUTmf34

Changing lifestyles and rising populations are reshaping expectations for food—driving demand for both quantity and variety. To meet these challenges, Mitsui has partnered with ETG—a diverse enterprise with a strong presence across Africa and deep expertise in agricultural value chains. Explore our collaboration in this short documentary-style video, highlighting how Mitsui and ETG are working together to strengthen global food supply chains and support agricultural development. You can view the full-length video, “Global Food Supply,” here: https://lnkd.in/gaTzSWNk #mitsuiandco #ETG #Food #Africa #Zambia #Farmers360Link